ON
ONCY.US Oncolytics Biotech Inc
- Market cap
- USD 44.6M
- P/E
- -
- P/B
- 1,055.04x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ONCY.US undervalued?
Graham numberThe Graham number of Oncolytics Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncolytics Biotech Inc fundamental analysis
No fundamental analysis for Oncolytics Biotech Inc yet.
Oncolytics Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in i…
Full company profileOncolytics Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oncolytics Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -162K | -90.8K | -95.4K | -486K | -333K | -361K | -301K | -299K | -87.0K | -70.0K | - |
| Operating Income | -15.3M | -15.6M | -16.7M | -20.1M | -25.5M | -26.2M | -19.8M | -25.5M | -25.5M | -28.7M | -37.9M |
| EBITDA | -13.8M | -14.7M | -17.2M | -19.7M | -25.0M | -25.8M | -19.5M | -25.2M | -25.5M | -28.7M | -37.8M |
| Net Income | -15.1M | -15.6M | -17.0M | -45.6M | -22.5M | -26.3M | -18.3M | -20.9M | -22.8M | -28.8M | -37.9M |
| EPS | -1.20 | -1.12 | -1.06 | -2.06 | -0.56 | -0.49 | -0.32 | -0.31 | -0.30 | -0.30 | -0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 14.8M | 18.2M | 14.9M | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 20.2M | 10.4M | 5.83M |
| Total Liabilities | 4.07M | 9.87M | 8.67M | 19.8M | 9.59M | 9.78M | 10.8M | 11.3M | 14.2M | 15.6M | 13.3M |
| Shareholders' Equity | 10.7M | 8.28M | 6.20M | -108K | 24.8M | 36.1M | 26.5M | 27.6M | 5.98M | -5.21M | -7.50M |
| Cash & Short-term Investments | 14.1M | 11.8M | 13.7M | 14.1M | 31.2M | 41.3M | 32.1M | 34.9M | 15.9M | 7.14M | 2.43M |
| Total Debt | - | - | - | 506K | 402K | 655K | 373K | 423K | 1.06M | 773K | 410K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.5M | -14.9M | -11.9M | -19.9M | -22.1M | -22.4M | -17.2M | -21.4M | -19.9M | -20.1M | -29.8M |
| Capital Expenditure | 23.5K | 106K | 107K | 10.9K | 29.0K | 286K | 40.5K | 6.03K | 174K | 6.00K | 16.0K |
| Free Cash Flow | -12.5M | -15.0M | -12.0M | -19.9M | -22.1M | -22.7M | -17.2M | -21.5M | -20.1M | -20.1M | -29.8M |
| Ratios | |||||||||||
| ROE | -141.6% | -188.5% | -275.0% | - | -90.9% | -72.9% | -69.0% | -75.9% | -381.0% | - | - |
| ROA | -102.6% | -86.0% | -114.6% | -231.7% | -65.5% | -57.3% | -49.0% | -53.9% | -112.9% | -276.4% | -649.1% |
| Debt to Equity | - | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.18x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oncolytics Biotech Inc dividends
Oncolytics Biotech Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 10:95 on May 25, 2018.
Who owns Oncolytics Biotech Inc
- Insiders 1.66%
- Institutions 8.86%
- Public & others 89.48%
- Shares outstanding 131M
- Free float 126M
Top funds holding ONCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Invesco NASDAQ Future Gen 200 ETF | 140K | 0.11% | +1.92% | Oct 2026 |
| Victory Extended Market Index | 14.3K | 0.01% | +6.03% | Sep 2026 |
Top institutions holding ONCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Marshall Wace Asset Management Ltd | 745K | 0.57% | -13.31% | Jun 2026 |
| XTX Topco Ltd | 261K | 0.20% | +137.71% | Jun 2026 |
| SEEDS INVESTOR LLC | 258K | 0.20% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 201K | 0.15% | 0.00% | Jun 2026 |
| Connective Capital Management LLC | 186K | 0.14% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 170K | 0.13% | 0.00% | Jun 2026 |
| Tocqueville Asset Management L.P. | 147K | 0.11% | -1.34% | Jun 2026 |
| Everhart Financial Group, Inc. | 141K | 0.11% | +1.98% | Jun 2026 |
| Susquehanna International Group, LLP | 134K | 0.10% | +224.59% | Jun 2026 |
| PFG Investments, LLC | 128K | 0.10% | +142.53% | Jun 2026 |
| HRT FINANCIAL LLC | 126K | 0.10% | +443.19% | Jun 2026 |
| Amvescap Plc. | 101K | 0.08% | 0.00% | Jun 2026 |
| Doliver Capital Advisors, Inc. | 100K | 0.08% | 0.00% | Jun 2026 |
| LPL Financial Corp | 80.3K | 0.06% | +1.79% | Jun 2026 |
| Franklin Templeton Inc | 79.8K | 0.06% | +14.32% | Jun 2026 |
| CIBC World Markets Inc. | 69.3K | 0.05% | +14.92% | Jun 2026 |
| Geode Capital Management, LLC | 66.9K | 0.05% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 57.4K | 0.04% | 0.00% | Jun 2026 |
| Fifth Third Bancorp | 45.5K | 0.03% | 0.00% | Jun 2026 |
| Head & Associates, LLC | 44.7K | 0.03% | 0.00% | Jun 2026 |
Oncolytics Biotech Inc company profile
- Company name
- Oncolytics Biotech Inc
- Ticker
- ONCY.US
- Exchange
- USA Stocks
- Listed since
- Nov 8, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 4350 Executive Drive, San Diego, CA, United States, 92121
- Phone
- 403 670 7377
- Website
- oncolyticsbiotech.com
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Oncolytics Biotech Inc management
9- Mr. Jared Kelly J.D., L.L.M.CEO & Director · born 1986
- Mr. Kirk J. Look C.A., CPAChief Financial Officer · born 1972
- Dr. Thomas C. Heineman M.D., Ph.D.Chief Medical Officer · born 1959
- Mr. John McAdoryChief Operating Officer · born 1977
- Ms. Allison Hagerman P.Eng., P.M.P.Chief Technology Officer · born 1984
- Jon PattonDirector of Investor Relations & Communication
- Mr. Andrew P. AromandoChief Business Officer · born 1969
- Yujun WuVP & Head of Biostatistics
- Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.Consultant